サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1429509

がん免疫治療薬の世界市場レポート 2024年

Immuno-Oncology Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 250 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
がん免疫治療薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

がん免疫治療薬の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には13.5%の年間複合成長率（CAGR）で1,750億5,000万米ドルに成長すると予想されます。予測期間で予想される成長は、がん免疫学への投資の増加、がん治療のための免疫療法薬への重点の高まり、戦略的提携を通じて達成された製品革新、市場を牽引すると予想される高齢者人口の増加に起因すると考えられます。予測期間の重要な動向には、バイオアベイラビリティを高め、皮下経路に関連する副作用を軽減するためのマイクロニードルインジェクターベースの医薬品の開発が含まれます。企業は、特定の患者プロファイルに合わせた個別化腫瘍薬の開発への投資を検討し、市場シェアを拡大して製品ポートフォリオを拡大するための買収を検討し、収益と市場シェアを拡大するために次世代生物製剤の開発に注力し、優先順位を付けることが推奨されます。がん治療のための抗体薬物複合体の作成。さらに、研究開発コストを削減し開発時間を節約するためのAIソリューションへの投資、新しい腫瘍薬の試験のための3Dプリンティングデバイスの採用、イノベーションとカテゴリーのリーダーシップのための免疫腫瘍学併用療法の探索、と推進のためのCAR-T療法の導入などです。イノベーションとカテゴリーのリーダーシップの確立が推奨される戦略です。

がん免疫治療薬市場の成長は、世界のがん症例の増加によって促進されると予想されます。特に、米国がん協会は2022年1月に、米国だけで190万人が新たにがんと診断され、60万9,360人ががん関連で死亡すると予測されていると報告し、問題の深刻さを浮き彫りにしています。肺がん、前立腺がん、腸がん、女性乳がんなど、世界で最も蔓延している種類のがんは、合計すると新規がん症例全体の43%を占めています。がんの罹患率が世界的に上昇しているため、今後数年間でがん免疫治療薬の需要が急増すると予想されます。

医療支出の拡大は、がん免疫治療薬市場の重要な促進要因として認識されています。医療支出は、個人、組織、または政府が医療関連の商品やサービスに割り当てた財源の総額を指し、がん免疫治療薬の開発、アクセシビリティ等、利用における重要な決定要因です。Centers for Medicare & Medicaid Services（CMS）によると、2021年の米国の医療支出は2.7％増の4兆3,000億米ドルに達しました。この医療支出の大幅な増加により、がん免疫治療薬の進歩が促進され、最終的にはがん治療の成果とこれらの革新的な治療法への患者のアクセスが向上すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界のがん免疫治療薬市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界のがん免疫治療薬の市場規模実績と成長、2018～2023年
  • 世界のがん免疫治療薬市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界のがん免疫治療薬市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • モノクローナル抗体
  • 免疫チェックポイント阻害剤
  • 免疫システム調節因子
  • がんワクチン
  • その他
  • 世界のがん免疫治療薬市場、治療用途別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 黒色腫
  • 肺がん
  • 血液がん
  • 腎細胞がん
  • 前立腺がん
  • 膀胱がん
  • その他
  • 世界のがん免疫治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 病院
  • クリニック
  • 外来手術センター
  • がん研究

第7章 地域と国の分析

  • 世界のがん免疫治療薬市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
  • 世界のがん免疫治療薬市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • がん免疫治療薬市場の競合情勢
  • がん免疫治療薬市場の企業プロファイル
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co.
    • Bristol-Myers Squibb Company
    • Amgen Inc
    • Johnson &Johnson

第31章 その他の大手と革新的な企業

  • AstraZeneca Plc
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Arlak Biotech
  • Healthkind Labs Pvt. Ltd.
  • SwisscheM Healthcare Pvt.Ltd
  • Apikos Pharma
  • Kolaz biotech
  • CStone Pharma
  • CARsgen Therapeutics
  • JW Therapeutics
  • BeiGene
  • Takeda Pharmaceuticals

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

目次
Product Code: r14480

Immuno-oncology drugs constitute a form of therapy or cancer treatment that utilizes drugs to either enhance or suppress the immune system, aiming to fortify the body's defenses against cancer, infections, and other disorders. These drugs leverage chemicals produced naturally by the body or synthesized in a laboratory to reinforce the immune system's capabilities, aiding the body in identifying and eliminating cancer cells.

The primary categories within the immuno-oncology drugs market include monoclonal antibodies, immune checkpoint inhibitors, immune system modulators, cancer vaccines, and others. Monoclonal antibodies are produced through the cloning of a single white blood cell, with each subsequent antibody traceable back to a single parent cell. Various therapeutic applications encompass melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer, and others. The application of immuno-oncology drugs spans sectors such as hospitals, clinics, ambulatory surgical centers, and cancer research institutes.

The immuno-oncology drugs market research report is one of a series of new reports from The Business Research Company that provides immuno-oncology drugs market statistics, including industry global market size, regional shares, competitors with an immuno-oncology drugs market share, detailed immuno-oncology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the immuno-oncology drugs industry. This immuno-oncology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immuno-oncology drugs market size has grown rapidly in recent years. It will grow from $92.78 billion in 2023 to $105.64 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The expansion observed in the historical period can be attributed to the increase in the number of cancer cases, robust economic growth in emerging markets, heightened healthcare expenditure, and a rise in pharmaceutical research and development (R&D) spending. However, the market faced constraints due to factors such as the high cost of immuno-oncology therapies, limited healthcare access, pricing pressures from regulators, elevated R&D costs, and the expiration of patents for certain drugs.

The immuno-oncology drugs market size is expected to see rapid growth in the next few years. It will grow to $175.05 billion in 2028 at a compound annual growth rate (CAGR) of 13.5%. The anticipated growth in the forecast period can be attributed to increasing investments in immuno-oncology, a growing emphasis on immunotherapy drugs for cancer treatment, product innovations achieved through strategic collaborations, and the rising geriatric population, which is expected to drive the market. Significant trends in the forecast period include the development of microneedle injector-based drugs to enhance bioavailability and mitigate side effects associated with the subcutaneous route. Companies are advised to consider investing in the development of personalized oncology drugs tailored to specific patient profiles, explore acquisitions to increase market shares and expand product portfolios, focus efforts on the development of next-generation biologics to boost revenue and market share, and prioritize the creation of antibody-drug conjugates for cancer treatment. Additionally, investments in AI solutions to reduce R&D costs and save development time, the adoption of 3D printing devices for testing new oncology drugs, exploration of immune-oncology combination therapies for innovation and category leadership, and the implementation of CAR-T therapies to drive innovation and establish category leadership are recommended strategies.

The growth of the immuno-oncology drugs market is expected to be fueled by the global increase in cancer cases. Notably, the American Cancer Society reported in January 2022 that the US alone is projected to witness 1.9 million new cancer diagnoses and 609,360 cancer-related deaths, highlighting the severity of the issue. The most prevalent types of cancer globally, including lung, prostate, bowel, and female breast cancer, collectively account for 43% of all new cancer cases. As cancer incidence rates rise globally, there is an anticipated surge in demand for immuno-oncology drugs in the coming years.

The expansion of healthcare expenditure is identified as a significant driver for the immuno-oncology drugs market. Healthcare expenditure, denoting the total financial resources allocated by individuals, organizations, or governments for healthcare-related goods and services, is a key determinant in the development, accessibility, and utilization of immuno-oncology drugs. In 2021, U.S. health care spending reached $4.3 trillion, growing by 2.7 percent, according to the Centers for Medicare & Medicaid Services (CMS). This substantial increase in healthcare spending is expected to drive advancements in immuno-oncology drugs, ultimately enhancing cancer treatment outcomes and patient access to these innovative therapies.

Companies operating in the immuno-oncology drugs market are actively engaging in strategic collaborations to foster product innovation. In response to the intensifying competition in this market, companies are not only focusing on developing groundbreaking products but also leveraging partnerships to share expertise and skills. An example of this collaborative trend is the agreement between Boehringer Ingelheim, a Germany-based pharmaceutical company, and OSE Immunotherapeutics, a France-based biotechnology company. This collaboration, announced in September 2021, aims to develop a novel checkpoint inhibitor for treating advanced solid tumors.

Major players in the immuno-oncology drugs market are concentrating on product development to diversify their cancer therapy portfolios. Tebentafusp-TEBN, a novel immuno-oncology drug, is a notable product in this context. It combines a T-cell receptor (TCR) with an anti-CD3 antibody fragment, designed to target and engage T cells with cancer cells, particularly melanoma. Immunocore, a UK-based biotechnology company, received FDA approval for KIMMTRAKR (Tebentafusp-TEBN) in January 2022. This approval marks a significant milestone as KIMMTRAKR is the first FDA-approved treatment for unresectable or metastatic uveal melanoma, showcasing its potential to extend overall survival.

In December 2021, Sanofi S.A., a France-based biopharmaceutical and healthcare company, completed the acquisition of Amunix Pharmaceuticals, Inc., for $1 billion. This strategic move enhances Sanofi's capabilities in developing innovative cancer medicines, particularly in the realm of immuno-oncology. The acquisition positions Sanofi to bring potentially superior and safer treatment candidates to patients by leveraging its expertise and collaborating as a center of excellence, thereby strengthening its oncology pipeline. Amunix Pharmaceuticals, Inc., a US-based biopharmaceutical company, specializes in the discovery and development of novel immuno-oncology drugs.

Major companies operating in the immuno-oncology drugs market report are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc., Johnson & Johnson, AstraZeneca PLC, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd., Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc., Otsuka Pharmaceutical Co, Ltd., Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., GlaxoSmithKline PLC, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, European Medical Center (EMC), Yauza Medical Center, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, CSC Pharmaceuticals International, Blanver EN, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals, Eurolab

North America was the largest region in the immuno-oncology drugs market in 2023. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the immuno-oncology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The immuno-oncology drugs market consists of sales of bevacizumab, alectinib, ibrutinib, imatinib, and palbociclib. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immuno-Oncology Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on immuno-oncology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immuno-oncology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The immuno-oncology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Immune Checkpoint Inhibitors; Immune System Modulators; Other Monoclonal Antibodies; Cancer Vaccines; Others
  • 2) By Therapeutic Application: Melanoma; Lung Cancer; Blood Cancer; Renal Cell Carcinoma; Bladder Cancer; Other Therapeutic Application
  • 3) By End-Users: Hospitals; Clinics; Ambulatory Surgical Centers; Others
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co.; Bristol-Myers Squibb Company; Amgen Inc; Johnson & Johnson
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Immuno-Oncology Drugs Market Characteristics

3. Immuno-Oncology Drugs Market Trends And Strategies

4. Immuno-Oncology Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Immuno-Oncology Drugs Market Size and Growth

  • 5.1. Global Immuno-Oncology Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Immuno-Oncology Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Immuno-Oncology Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Immuno-Oncology Drugs Market Segmentation

  • 6.1. Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Monoclonal Antibodies
  • Immune Checkpoint Inhibitors
  • Immune System Modulators
  • Cancer Vaccines
  • Other Types
  • 6.2. Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Melanoma
  • Lung Cancer
  • Blood Cancer
  • Renal Cell Carcinoma
  • Prostate Cancer
  • Bladder Cancer
  • Other Therapeutic Applications
  • 6.3. Global Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Cancer Research Institutes

7. Immuno-Oncology Drugs Market Regional And Country Analysis

  • 7.1. Global Immuno-Oncology Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Immuno-Oncology Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Immuno-Oncology Drugs Market

  • 8.1. Asia-Pacific Immuno-Oncology Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Immuno-Oncology Drugs Market

  • 9.1. China Immuno-Oncology Drugs Market Overview
  • 9.2. China Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Immuno-Oncology Drugs Market

  • 10.1. India Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Immuno-Oncology Drugs Market

  • 11.1. Japan Immuno-Oncology Drugs Market Overview
  • 11.2. Japan Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Immuno-Oncology Drugs Market

  • 12.1. Australia Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Immuno-Oncology Drugs Market

  • 13.1. Indonesia Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Immuno-Oncology Drugs Market

  • 14.1. South Korea Immuno-Oncology Drugs Market Overview
  • 14.2. South Korea Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Immuno-Oncology Drugs Market

  • 15.1. Western Europe Immuno-Oncology Drugs Market Overview
  • 15.2. Western Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Immuno-Oncology Drugs Market

  • 16.1. UK Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Immuno-Oncology Drugs Market

  • 17.1. Germany Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Immuno-Oncology Drugs Market

  • 18.1. France Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Immuno-Oncology Drugs Market

  • 19.1. Italy Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Immuno-Oncology Drugs Market

  • 20.1. Spain Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Immuno-Oncology Drugs Market

  • 21.1. Eastern Europe Immuno-Oncology Drugs Market Overview
  • 21.2. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Immuno-Oncology Drugs Market

  • 22.1. Russia Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Immuno-Oncology Drugs Market

  • 23.1. North America Immuno-Oncology Drugs Market Overview
  • 23.2. North America Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Immuno-Oncology Drugs Market

  • 24.1. USA Immuno-Oncology Drugs Market Overview
  • 24.2. USA Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Immuno-Oncology Drugs Market

  • 25.1. Canada Immuno-Oncology Drugs Market Overview
  • 25.2. Canada Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Immuno-Oncology Drugs Market

  • 26.1. South America Immuno-Oncology Drugs Market Overview
  • 26.2. South America Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Immuno-Oncology Drugs Market

  • 27.1. Brazil Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Immuno-Oncology Drugs Market

  • 28.1. Middle East Immuno-Oncology Drugs Market Overview
  • 28.2. Middle East Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Immuno-Oncology Drugs Market

  • 29.1. Africa Immuno-Oncology Drugs Market Overview
  • 29.2. Africa Immuno-Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Immuno-Oncology Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Immuno-Oncology Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Immuno-Oncology Drugs Market Competitive Landscape
  • 30.2. Immuno-Oncology Drugs Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck & Co.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bristol-Myers Squibb Company
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Amgen Inc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Johnson & Johnson
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Immuno-Oncology Drugs Market Other Major And Innovative Companies

  • 31.1. AstraZeneca Plc
  • 31.2. Eli Lilly and Company
  • 31.3. Novartis International AG
  • 31.4. Pfizer Inc.
  • 31.5. Sanofi S.A.
  • 31.6. Arlak Biotech
  • 31.7. Healthkind Labs Pvt. Ltd.
  • 31.8. SwisscheM Healthcare Pvt.Ltd
  • 31.9. Apikos Pharma
  • 31.10. Kolaz biotech
  • 31.11. CStone Pharma
  • 31.12. CARsgen Therapeutics
  • 31.13. JW Therapeutics
  • 31.14. BeiGene
  • 31.15. Takeda Pharmaceuticals

32. Global Immuno-Oncology Drugs Market Competitive Benchmarking

33. Global Immuno-Oncology Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Immuno-Oncology Drugs Market

35. Immuno-Oncology Drugs Market Future Outlook and Potential Analysis

  • 35.1 Immuno-Oncology Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Immuno-Oncology Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Immuno-Oncology Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer